We are now accepting applications for the T32 postdoctoral fellowship training program: Training in Oncology Population Sciences (TOPS)
Applications are due 12/16 and accepted fellows will begin their training in September 2027. https://t.co/z2Jiibzhiy
New work from Pasi A. Jänne, us, and 23andme; led by Jackie LoPiccolo and Steven Micheletti. Characterizing a highly penetrant germline founder mutation for lung cancer.
In our latest, we continued multi-omic exploration of GI neuroendocrine tumors, finding potential organ-specific molecular programs and microenvironmental niches - congrats Julie Karam @SamHoffmanMed et al! @DanaFarber@broadinstitute@jclinicalinvest https://t.co/Nss6nBHX4t
🚨We are hiring! 🚨
The Department of Biostatistics @HarvardChan and the Department of Data Science @DanaFarber are recruiting a tenure-track Assistant/Associate Professor in statistics or machine learning with interests in single-cell or spatial genomics.
Link below 👇
In our latest, we studied how certain immune cells surround bladder tumors and contribute to chemotherapy resistance, pointing to a surprising potential therapeutic target ...
Congrats @CarvalhoFilipeL@mouwlab et al! @CellPressNews@cellpressblue https://t.co/EcC0AXH32c
Here's our latest in @cellpressblue. In collaboration with @VanAllenLab and @mouwlab, we asked a simple question:
Why do some muscle-invasive bladder cancers survive neoadjuvant chemotherapy? 🧵https://t.co/Q2q99ZRNbV
Congrats to @JihyunkaLee et al!
Very exciting new method for inferring latent disease trajectories, led by the tireless Dr. Urbut with Natarajan and Parmigiani labs. If you're considering a postdoc in this area talk to Sarah!
One of my first consults as a cardiology fellow: a 34-year-old, textbook MI. A day earlier, no risk model would have flagged him for prevention. That paradox has driven my work ever since — our models miss how disease actually evolves, dynamically, on top of a genetic background. @Nature https://t.co/PHDOjmGxE3
📣Delighted to share two new studies from our team
using germline genome sequencing 🧬
to understand #cancer#predisposition!
Interested? 🧵👇 for details
1/15
Using burgers as a model system, a generative AI system rediscovers the classic Big Mac without explicit supervision and generates novel burgers optimized for deliciousness, sustainability, or nutrition, according to a paper in npj Science of Food. https://t.co/rrgUL1uQzj
1/ Results from #ARC20 trial are out in @Nature!
This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response. This is the 2nd HIF2 inhibitor with enough activity to move to a pivotal study after Belzutifan, cementing the 2019 @nobelprize story with @kaelinlab et al
Check it out: https://t.co/ZCBMtlx8VP
In our latest, we tested elements of cancer biology research using @AnthropicAI AI agents, with varying amounts of human involvement across multi-step, multi-omic analyses
Interesting times for agentic AI & biological discovery, and for the future of (cancer) biology research...
We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.
It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.
The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.
We are looking for someone to start ASAP! More information here:
https://t.co/RgV4lJw4OM
Please help to spread the word and RT!
@DrChoueiri@VanAllenLab@tompowles1@YaleCancer@YaleMed@SmilowCancer@kidneycan@OncoAlert@OncLive@KidneyCancer@A_P_S_A@cure_today@yalepathology@Yale_Urology@DrYukselUrun@MarkDSiegel1@OncBrothers@DrKarineTawagi